CELL & GENE THERAPY

Cell & Gene Therapy, Friday 2 March 2018

09:00

Organiser's Welcome Remarks

09:05

Chair's Opening Remarks

Disruption & Digitalisation

Tony Liu
09:10

Shifting paradigm of the advanced therapy landscape in Asia

Recently raised to fame as the new miracle method to treat even the most stubborn cancer cases, CAR-T trials have proven to save patients who have failed all known treatment. From a pharma perspective, what methods can they adopt to produce these highly personalised, customised treatments at scale? Upon approval for commercial deployment, what else needs to be done to help patients afford the sky high cost of immunotherapy? Join this thought provoking presentation to hear from Tony Liu, CEO of CBMG and former senior executive of Alibaba and Microsoft to learn how this influential biopharma company take steps to prepare for the next miracle drug in making. 
Antonio Lee
09:30

Innovation beyond limit: How do we conquer incurable diseases and create new history

Advancement in research helps to push the limitation of treatment paradigm to attempt curing currently incurable diseases. Innovative therapeutic solutions however is often not sufficient without a strong team to help with commercialisation. In this presentation, Antonio will share about the overall landscape in Asia stem cell therapy, challenges in current landscape and opportunities ahead to achieve commercial excellence.  
Ivor Lim
09:50

Educated guesses, lofty aspirations, hard realities

Ideas are free and to be able to catch one by the wings and bring it back to ground is a wonderful feeling indeed. For doctors, the next step is to bring this good idea into the wards for the patient’s benefit. The transition of bench research to bedside application seems very straightforward at first glance, but it is not until the first steps are taken that one realises the numerous hurdles that have to be surmounted in order to achieve this. In the best interests of the patient, this translational sequence is prescriptive and tedious, and yet it pays no heed to other essentials crucial for the translational effort to be truly successful. This presentation also shares the journey of CellResearch Corporation which 13 years to see the light at the end of the tunnel.
10:10

Exhibition Visit & Networking Refreshments

B N Manohar
Cell & Gene Therapy
10:50

Chair's Opening Remarks

ADVANCED THERAPY LANDSCAPE

Kenji Kakuta
Cell & Gene Therapy
11:00

Regenerative medicine by iPSC in Japan

Lei Xiao
Cell & Gene Therapy
11:20

What’s next after CAR-T in Leukaemia treatment?

CAR-T cell therapy is a combination of cell, gene and immunotherapy and it is finally here, to serve as an alternative cancer treatment. Starting with Leukaemia, CAR-T has been tested on solid tumours, genetic diseases and more. What’s Asia role in the CAR-T I-O field and how do we keep up with global trends?
Tagle Danilo A
Cell & Gene Therapy
11:40

Innovative tools for risk assessment in drug development

Approximately 30% of drugs have failed in human clinical trials due to adverse reactions despite promising pre-clinical studies, and another 60% fail due to lack of efficacy. There is a need for better and more predictive tools to address this challenge in drug development.  The NIH MPS program is developing alternative approaches for more reliable readouts of toxicity or efficacy. Tissue chips are bioengineered systems utilizing chip technology and microfluidics that mimic tissue cytoarchitecture and functional units of human organs. These microfabricated devices are useful for modelling human diseases, and for studies in precision medicine and environment exposures.
12:20

Exhibition Visit & Networking Lunch

13:40

Chair's Opening Remarks

Alfred Scheidegger
13:45

How to Capture Value in a Fast-Paced, Disruptive Industry

Cell & Gene Therapy
13:45

Nanocell platform for the targeted cyto-immunotherapy in cancer

Danny Yeung
14:05

Pharma 4.0: How digitisation & disruption are creating a need for agility and entrepreneurship in pharma

Digitisation is changing the way pharma interacts with payers, doctors and patients, leading pharma to seek out different skills and personality traits in employees. The challenge is selecting the right disruptor to foster a forward-thinking organisation, and identifying the suitable digital strategy whilst also complying with local regulations and continuing to invest in core R&D capabilities. Hear from big pharma on how they are moving forward and embracing the digital disruption.
 
Sebastian Sujka
14:25

AI in pharma: Using digital technology for disease prevention

14:45

Exhibition Visit & Networking Refreshments

ADVANCED THERAPIES POST DEVELOPMENT

Prathibha Shetty
Cell & Gene Therapy
15:15

Case study: What it takes to achieve commercial success for cell & gene therapy products

The uphill path towards commercial success of cell & gene therapy is costly and time extensive. So how do we get there?
B N Manohar
Cell & Gene Therapy
15:35

Cell Therapy for treating Critical Limb Ischemia – an unmet medical need

Critical Limb Ischemia (CLI) is a Peripheral arterial disease (PAD) in the legs, sometimes known as peripheral vascular disease, is frequently caused by atheroma (fatty deposits) in the walls of the arteries, leading to insufficient blood flow to the muscles and other tissues. CLI is a major healthcare issue worldwide and patients with CLI have an increased risk of mortality, myocardial infarction and cerebrovascular disease. The predicted increase in the prevalence of CLI will intensify the demands placed on the healthcare services in India and around the globe. There is therefore a pressing need within the healthcare system to commence an effective therapeutic strategy for treating patients with CLI. Stem Cell therapy likely to address the gaps in the treatment of CLI due to 1) Anti –inflammatory properties 2) Ability to promote neovascularization and 3) promote healing of non-healing ischemic ulcers.
Kesavan Karthikeyan
Cell & Gene Therapy
15:55

Mucoadhesive nano-carrier as non-viral vector for ocular gene therapy for the management of glaucoma

Glaucoma is the second leading cause of blindness with 60.5 million patients worldwide in 2010, a figure that is expected to increase to 79.6 million by 2020. Find out how gene therapy helps to treat ocular disorders using mucoadhesive nanocarrier as vector for the treatment.

Close of Phar-East 2018

last published: 14/Feb/18 03:55